Wart Remover Ointment
NDC Package 84288-005-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Wart Remover (salicylic acid, chlorhexidine) ointment is after cleansing the areas to betreat-edwithlukewarm water,apply proper amou-ntofthecream to the surface of theaffectedareaandgentlyrub infor 5-10 minutes untilit is fullyabsorbed.itisrecommendedtousethis productcontinuously2-3 times aday un-til the wartsfalloff. This formulation utilizes a ointment delivery system. Marketed by Dongkou County Hecheng Network Technology Co., Ltd., this product is identified by NDC 84288-005 and is authorized under FDA application M028.

Identification & Billing

NDC Package Code
84288-005-01
Package Description
20 g in 1 TUBE
Product Code
84288-005
11-Digit Billing Format
84288000501
RxNorm Crosswalk
  • RxCUI: 2682584 - chlorhexidine 1 % / salicylic acid 1 % Topical Ointment
  • RxCUI: 2682584 - chlorhexidine 0.01 MG/MG / salicylic acid 0.01 MG/MG Topical Ointment

Clinical Specifications

Proprietary Name
Wart Remover
Non-Proprietary Name
Salicylic Acid, Chlorhexidine
Substance Name
Chlorhexidine; Salicylic Acid
Dosage Form
Ointment - A semisolid3 dosage form, usually containing <20% water and volatiles5 and >50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Pharmacologic Class
Decreased Cell Wall Integrity - [PE] (Physiologic Effect)
Usage Information
After cleansing the areas to betreat-edwithlukewarm water,apply proper amou-ntofthecream to the surface of theaffectedareaandgentlyrub infor 5-10 minutes untilit is fullyabsorbed.itisrecommendedtousethis productcontinuously2-3 times aday un-til the wartsfalloff.

Regulatory & Marketing

Labeler Name
Dongkou County Hecheng Network Technology Co., Ltd.
Product Type
Human Otc Drug
FDA Application #
M028
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
08-02-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 84288-005-01 identifies a specific commercial package of 20 g in 1 tube of Wart Remover, a human over the counter drug labeled by Dongkou County Hecheng Network Technology Co., Ltd.. This ointment is formulated for topical use and contains chlorhexidine; salicylic acid as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dongkou County Hecheng Network Technology Co., Ltd. on August 02, 2024. The current certification is valid through December 31, 2026.

How is this Dongkou County Hecheng Network Technology Co., Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 84288000501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
84288-005-01
11-Digit CMS (5-4-2)
84288-0005-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.